Jan Philipp Bewersdorf1, Cecily Allen2, Abu-Sayeef Mirza2, Alyssa A Grimshaw3, Smith Giri4, Nikolai A Podoltsev5, Lohith Gowda2, Christina Cho6, Martin S Tallman7, Amer M Zeidan5, Maximilian Stahl8. 1. Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut. 2. Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut. 3. Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, Connecticut. 4. Division of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, Alabama. 5. Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut. 6. Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medical Oncology, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: maximilian_stahl@dfci.harvard.edu.
Abstract
BACKGROUND: Disease relapse remains the major cause of death among patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who receive an allogeneic hematopoietic cell transplant (allo-HCT). Maintenance treatment with FLT3 inhibitors and hypomethylating agents (HMA) has been studied in various clinical trials with mixed results. OBJECTIVE: To synthesize the current evidence on the efficacy and safety of FLT3 inhibitors and HMA for maintenance therapy after allo-HCT in AML and MDS. METHODS: For this systematic review and meta-analysis Cochrane Library, Google Scholar, Ovid Medline, Ovid Embase, PubMed, Scopus, and Web of Science Core Collection were searched from inception to March 2021 for studies on maintenance therapies after allo-HCT in AML and MDS. Studies were excluded if they were reviews, commentaries, case series with <5 patients, or basic research articles, not published in English, not on post-allo-HCT maintenance with FLT3 inhibitors or HMA in AML or MDS, or if they were clinical trials without published results or duplicate publications from the same patient cohort. Studies with insufficient reporting of the primary endpoint (2-year overall survival [OS]) and studies using FLT3 inhibitors or HMA for pre-emptive treatment of imminent relapse based on positive measurable residual disease testing were excluded. Random-effects models were used to pool response rates for the primary outcome of 2-year OS. Hazard ratios (HR) for death and relapse were calculated for studies that included a control group. Rates of relapse-free survival (RFS), non-relapse mortality, and acute and chronic graft-versus-host-disease (GVHD) were studied as secondary endpoints. Downs and Black checklist and risk of bias assessments were used to gauge the quality of individual studies. The study protocol has been registered on PROSPERO (CRD42020187298). RESULTS: Our search strategy identified 5559 studies. Twenty-one studies with a total of 809 patients were included in the meta-analysis. The 2-year OS rates were 81.7% (95% confidence interval [CI], 73.8%-87.7%) and 65.7% (95% CI, 55.1%-74.9%) among patients treated with FLT3 inhibitors and HMA, respectively. In sensitivity analyses restricted to studies that included a control group, maintenance therapy with FLT3 inhibitors (HR for death = 0.41; 95% CI, 0.26-0.62) or HMA (HR = 0.45; 95% CI, 0.31-0.66) appeared superior to no maintenance therapy. The 2-year RFS rates were 79.8% (95% CI, 75.0%-83.9%) and 62.4% (95% CI, 50.6%-72.9%) among patients treated with FLT3 inhibitors and HMA, respectively. Rates of any grade acute and chronic GVHD were 33.1% (95% CI, 25.4%-41.8%; grade 3/4: 16.5%) and 42.5% (95% CI, 26.3%-60.4%) among FLT3 inhibitor and 42.7% (95% CI, 33.5%-52.4%; grade 3/4: 8.1%) and 41.5% (95% CI, 32.0%-51.6%) among HMA-treated patients, respectively. CONCLUSION: Maintenance therapy with either FLT3 inhibitors or HMA after allo-HCT can lead to prolonged and improved OS and RFS with a favorable safety profile. Additional studies are needed to define the optimal duration of treatment, the role of measurable residual disease status, and transplant characteristics in patient selection.
BACKGROUND: Disease relapse remains the major cause of death among patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who receive an allogeneic hematopoietic cell transplant (allo-HCT). Maintenance treatment with FLT3 inhibitors and hypomethylating agents (HMA) has been studied in various clinical trials with mixed results. OBJECTIVE: To synthesize the current evidence on the efficacy and safety of FLT3 inhibitors and HMA for maintenance therapy after allo-HCT in AML and MDS. METHODS: For this systematic review and meta-analysis Cochrane Library, Google Scholar, Ovid Medline, Ovid Embase, PubMed, Scopus, and Web of Science Core Collection were searched from inception to March 2021 for studies on maintenance therapies after allo-HCT in AML and MDS. Studies were excluded if they were reviews, commentaries, case series with <5 patients, or basic research articles, not published in English, not on post-allo-HCT maintenance with FLT3 inhibitors or HMA in AML or MDS, or if they were clinical trials without published results or duplicate publications from the same patient cohort. Studies with insufficient reporting of the primary endpoint (2-year overall survival [OS]) and studies using FLT3 inhibitors or HMA for pre-emptive treatment of imminent relapse based on positive measurable residual disease testing were excluded. Random-effects models were used to pool response rates for the primary outcome of 2-year OS. Hazard ratios (HR) for death and relapse were calculated for studies that included a control group. Rates of relapse-free survival (RFS), non-relapse mortality, and acute and chronic graft-versus-host-disease (GVHD) were studied as secondary endpoints. Downs and Black checklist and risk of bias assessments were used to gauge the quality of individual studies. The study protocol has been registered on PROSPERO (CRD42020187298). RESULTS: Our search strategy identified 5559 studies. Twenty-one studies with a total of 809 patients were included in the meta-analysis. The 2-year OS rates were 81.7% (95% confidence interval [CI], 73.8%-87.7%) and 65.7% (95% CI, 55.1%-74.9%) among patients treated with FLT3 inhibitors and HMA, respectively. In sensitivity analyses restricted to studies that included a control group, maintenance therapy with FLT3 inhibitors (HR for death = 0.41; 95% CI, 0.26-0.62) or HMA (HR = 0.45; 95% CI, 0.31-0.66) appeared superior to no maintenance therapy. The 2-year RFS rates were 79.8% (95% CI, 75.0%-83.9%) and 62.4% (95% CI, 50.6%-72.9%) among patients treated with FLT3 inhibitors and HMA, respectively. Rates of any grade acute and chronic GVHD were 33.1% (95% CI, 25.4%-41.8%; grade 3/4: 16.5%) and 42.5% (95% CI, 26.3%-60.4%) among FLT3 inhibitor and 42.7% (95% CI, 33.5%-52.4%; grade 3/4: 8.1%) and 41.5% (95% CI, 32.0%-51.6%) among HMA-treated patients, respectively. CONCLUSION: Maintenance therapy with either FLT3 inhibitors or HMA after allo-HCT can lead to prolonged and improved OS and RFS with a favorable safety profile. Additional studies are needed to define the optimal duration of treatment, the role of measurable residual disease status, and transplant characteristics in patient selection.
Authors: Firas El Chaer; Uma Borate; Rémy Duléry; Shernan G Holtan; Arjun Datt Law; Lori Muffly; Samah Nassereddine; Rory M Shallis; Kate Stringaris; Justin Taylor; Steven M Devine; Mohamad Mohty; Christopher S Hourigan Journal: Blood Adv Date: 2021-03-23
Authors: C Anthias; F L Dignan; R Morilla; A Morilla; M E Ethell; M N Potter; B E Shaw Journal: Bone Marrow Transplant Date: 2014-02-10 Impact factor: 5.483
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: A-L Herr; M Labopin; D Blaise; N Milpied; M Potter; M Michallet; W Heit; F Ferrara; J Esteve; W Arcese; G Ehninger; J M Rowe; G Kobbe; A Rosselet; D Bunjes; B Rio; M Brune; A Nagler; N C Gorin; F Frassoni; V Rocha Journal: Leukemia Date: 2006-11-23 Impact factor: 11.528
Authors: Wael Saber; Jennifer Le Rademacher; Mikkael Sekeres; Brent Logan; Moira Lewis; Adam Mendizabal; Eric Leifer; Frederick R Appelbaum; Mary M Horowitz; Ryotaro Nakamura; Corey S Cutler Journal: Biol Blood Marrow Transplant Date: 2014-06-24 Impact factor: 5.742
Authors: N Basara; A Schulze; U Wedding; M Mohren; A Gerhardt; C Junghanss; N Peter; G Dölken; C Becker; S Heyn; C Kliem; T Lange; R Krahl; W Pönisch; H-J Fricke; H G Sayer; H Al-Ali; F Kamprad; D Niederwieser Journal: Leukemia Date: 2009-01-08 Impact factor: 11.528
Authors: Celalettin Ustun; Jennifer Le-Rademacher; Hai-Lin Wang; Megan Othus; Zhuoxin Sun; Brittny Major; Mei-Jie Zhang; Elizabeth Storrick; Jacqueline M Lafky; Selina Chow; Krzysztof Mrózek; Eyal C Attar; Such Nand; Clara D Bloomfield; Larry D Cripe; Martin S Tallman; Frederick Appelbaum; Richard A Larson; Guido Marcucci; Gail J Roboz; Geoffrey L Uy; Richard M Stone; Aminah Jatoi; Thomas C Shea; Marcos de Lima; James M Foran; Brenda M Sandmaier; Mark R Litzow; Harry P Erba; Arti Hurria; Daniel J Weisdorf; Andrew S Artz Journal: Leukemia Date: 2019-05-09 Impact factor: 11.528
Authors: Christopher S Hourigan; Laura W Dillon; Gege Gui; Brent R Logan; Mingwei Fei; Jack Ghannam; Yuesheng Li; Abel Licon; Edwin P Alyea; Asad Bashey; H Joachim Deeg; Steven M Devine; Hugo F Fernandez; Sergio Giralt; Mehdi Hamadani; Alan Howard; Richard T Maziarz; David L Porter; Bart L Scott; Erica D Warlick; Marcelo C Pasquini; Mitchell E Horwitz Journal: J Clin Oncol Date: 2019-12-20 Impact factor: 44.544
Authors: Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis Journal: Biol Blood Marrow Transplant Date: 2015-09-09 Impact factor: 5.742
Authors: Smith Kungwankiattichai; Ben Ponvilawan; Claudie Roy; Pattaraporn Tunsing; Florian Kuchenbauer; Weerapat Owattanapanich Journal: Front Med (Lausanne) Date: 2022-02-15